InvestSMART

Vitasora Health Limited (ASX: VHL) - Announcements

Current share price for VHL : $0.013 0.001 (8.33%)+

ASX company news and announcements for Vitasora Health Limited (VHL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Vitasora Health Limited (VHL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Vitasora Health Limited (VHL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Vitasora Health Limited (VHL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$31 Vitasora USA Momentum- Virtual Briefing on Key Developments 26 May 2025 3:49PM $0.041 $0.013 fallen by 68.29%
$31 Change of Directors' Interest Notices x2 20 May 2025 4:06PM $0.038 $0.013 fallen by 65.79%
$31 Section 708A Cleansing Notice 16 May 2025 9:11AM $0.045 $0.013 fallen by 71.11%
$31 Application for quotation of securities - VHL 16 May 2025 9:09AM $0.045 $0.013 fallen by 71.11%
$31 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2025 9:59AM $0.037 $0.013 fallen by 64.86%
$31 Change of OTC Ticker 24 Apr 2025 2:53PM $0.039 $0.013 fallen by 66.67%
$31 Prescient completes acquisition of AKTivate Therapeutics 11 Dec 2014 10:35AM $0.120 $0.013 fallen by 89.17%
$31 Appendix 4C - quarterly 3 Nov 2014 8:18AM $0.010 $0.013 risen by 30%
$31 VHL TO ACQUIRE DEEP AKT INHIBITOR PORTFOLIO 17 Oct 2014 9:57AM $0.007 $0.013 risen by 85.71%
$31 Trading Halt 15 Oct 2014 10:14AM $0.005 $0.013 risen by 160%
$31 FDA IND Re-Activation Request for Phase Ib/II Trial 9 Sep 2014 8:26AM $0.006 $0.013 risen by 116.67%
$31 Virax Holdings Appendix 4E and 2014 Financial Report 1 Sep 2014 8:14AM $0.006 $0.013 risen by 116.67%
$31 Appendix 4C - quarterly 31 Jul 2014 12:29PM $0.007 $0.013 risen by 85.71%
$31 VHL completes Pathway acquisiton, appoints new director 30 May 2014 1:22PM $0.008 $0.013 risen by 62.50%
$31 Appointment of Managing Director to Drive Cancer Programs 15 May 2014 10:26AM $0.008 $0.013 risen by 62.50%
$31 Disclosure Document 14 May 2014 7:07PM $0.008 $0.013 risen by 62.50%
$31 Capital Raising Update 9 May 2014 7:14PM $0.011 $0.013 risen by 18.18%
$31 Virax Option to Acquire Exclusive Worldwide Licence 5 May 2014 10:34AM $0.010 $0.013 risen by 30%
$31 Trading Halt 1 May 2014 11:52AM $0.010 $0.013 risen by 30%
$31 Appendix 4C - quarterly 30 Apr 2014 8:23AM $0.010 $0.013 risen by 30%
$31 Co-X-Gene Development Pipeline 24 Apr 2014 8:26AM $0.010 $0.013 risen by 30%
$31 Virax secures $3 million placement 25 Mar 2014 8:51AM $0.014 $0.013 fallen by 7.14%
$31 Trading Halt 21 Mar 2014 8:59AM $0.015 $0.013 fallen by 13.33%
$31 Virax to acquire advanced cancer platform from Yale Uni 17 Mar 2014 9:05AM $0.017 $0.013 fallen by 23.53%
$31 Trading Halt 14 Mar 2014 11:42AM $0.015 $0.013 fallen by 13.33%

76 - 100 of 195 results

Page 4 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.